Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. (Q48306002)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

title

Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

author name string

Diwakar Davar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

publication date

1 April 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

page(s)

125-140

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11523-017-0547-9

8 April 2020

exact match

0 references

cites work

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

L-arginine availability regulates T-lymphocyte cell-cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Immunological Relevance of the Coevolution of IDO1 and AHR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The role of IDO in brain tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Regulation of type I interferon responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Tolerogenic Phenotype of IFN-γ-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Ligand binding and activation of the Ah receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Different global gene expression profiles in benzo[a]pyrene- and dioxin-treated vascular smooth muscle cells of AHR-knockout and wild-type mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Aryl hydrocarbon receptor signaling regulates NF-κB RelB activation during dendritic-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Activation of the STING adaptor attenuates experimental autoimmune encephalitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Regulatory T cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

IDO activates regulatory T cells and blocks their conversion into Th17-like T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Reversing T-cell Dysfunction and Exhaustion in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The role of CTLA-4 in the regulation and initiation of T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

A phase I study of indoximod in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Inhibitor of indoleamine-2,3-dioxygenase 1-methyl-D-tryptophan can stimulate the growth of immunogenic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0547-9

Specific Induction of Pulmonary Indoleamine 2,3-Dioxygenase by Bacterial Lipopolysaccharide

21 January 2018

1 reference

12 December 2020

Analysis of interferon-gamma resistant mutants that are possibly defective in their signaling mechanism

1 reference

12 December 2020

Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung by bacterial lipopolysaccharide

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation

1 reference

12 December 2020

1 reference

12 December 2020

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

12 December 2020

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

12 December 2020

CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression

1 reference

12 December 2020

Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers

1 reference

12 December 2020

The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine

1 reference

12 December 2020

The conversion of tryptophan to kynurenine in liver. II. The enzymatic hydrolysis of formylkynurenine.

1 reference

12 December 2020

T cell apoptosis by kynurenines.

1 reference

12 December 2020

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells

1 reference

12 December 2020

Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer

1 reference

12 December 2020

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

12 December 2020

Expression of indoleamine 2,3-dioxygenase predicts shorter survival in patients with vulvar squamous cell carcinoma (vSCC) not influencing on the recruitment of FOXP3-expressing regulatory T cells in cancer nests

1 reference

12 December 2020

Indoleamine-pyrrole 2,3-dioxygenase might be a prognostic biomarker for patients with renal cell carcinoma

1 reference

12 December 2020

Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients

1 reference

12 December 2020

High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia

1 reference

12 December 2020

An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

1 reference

12 December 2020

The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma.

1 reference

12 December 2020

10.1007/S11523-017-0547-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29302770%20AND%20SRC:MED&resulttype=core&format=json

8 April 2020

1 reference